19:14:26 EDT Tue 16 Apr 2024
Enter Symbol
or Name
USA
CA



Cannabis Summary for Jan. 8, 2021

2021-01-08 20:19 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The S&P/TSX Cannabis Index lost 1.12 to 192.76, while the CSE Composite Index edged down a fraction to 756.84. Another U.S. MSO (multistate operator) is hopping aboard the financing bandwagon, taking advantage of a burst of enthusiasm among investors expecting pro-cannabis legislation from the newly Democrat-controlled Congress and White House. With Jushi Holdings Inc. (JUSH: $7.08) recently closing an oversubscribed financing for $40-million and Curaleaf Holdings Inc. (CURA: $17.38) proposing its own financing for at least $275-million, the latest MSO seeking to tap the market is Columbia Care Inc. (CCHW), down 70 cents to $8.05 on 4.06 million shares.

Columbia Care announced last night that it wants to raise $130-million at $8.05 a share. This price is below yesterday's close of $8.75, but well above the $5 that the stock was trading at just two months ago. They have been busy months for Colombia Care. Among other things, the company closed its $52.5-million acquisition of Project Cannabis in California, arranged the $240-million (U.S.) cash-and-share takeover of Green Leaf Medical in the mid-Atlantic region, and (just yesterday) paid $15-million to acquire its second store in the limited-licence market of San Diego, Calif. Clearly it has decided that its balance sheet could use a touch-up. As of Sept. 30, Columbia had $42-million (U.S.) in cash, which it gave a boost to in October with a $20-million (U.S.) debt financing. It says the new $130-million equity financing will go toward working capital and general purposes.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2024 Canjex Publishing Ltd. All rights reserved.


Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.


Comments for this item are closed